ArticleEClinicalMedicine2025
The national and subnational burden of multiple myeloma (MM) in Italy from 1990 to 2023: results from the global burden of disease study 2023.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is the second most common oncohematological neoplasm after Non-Hodgkin Lymphomas. The present study investigated the burden of MM and its temporal trends from 1990 to 2023, at the Italian national and subnational level (21 regions). Methods: We used the Global Burden of Disease Study 2023 estimates to describe the MM age-standardized incidence (ASIR), mortality (ASMR), years lived with disability (ASYLD), years of life lost (ASYLL), disability-adjusted life years (ASDR) rates, the related 1990-2023 crude all-ages and age-standardized annual rates of changes (ARC), as well the age-standardized mortality-to-incidence ratio (MIR). Finally, the national estimates for MM were compared to those for the GBD Global and High-middle Socio-Demographic Index (SDI) countries. Findings: In 2023 at the Italian national level, there were 6700 MM new cases, 4100 deaths and 73,600 DALYs, whose vast majority came from YLLs (93.4%). The 1990-2023 ARC for ASIR showed a stable trend, both overall (0.28; 95% UI -0.20 to 0.91) and among males (ARC 0.32; -0.15 to 0.92) and females (ARC 0.22; -0.30 to 0.95). The ARC for ASMR (0.04; -0.08 to 0.17) also showed a stable pattern, as well as the ARC for ASDR (-0.07; -0.20 to 0.06). The MIR improved over time, from 68.0 to 55.1, similarly for both sexes. At the subnational level, the ASIR was stable in all the 21 local entities, while the ASMR and ASDR significantly improved in 1 and 7 regions, respectively. Interpretation: Comparing the GBD Italian estimates to those for the GBD Global and High-middle SDI countries, the age-standardized incidence, mortality and DALYs rates were higher, but their ARC showed a much more favourable trend than for the High-middle SDI countries. The Italian subnational estimates, including the MIR, were in good agreement with the national data, with some geographical differences. Funding: This work was supported by the Italian Ministry of Health, through the contribution given to the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste-Italy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.